OBJECTIVES The aim of this study was to evaluate the consequences, measured as mortality and in-hospital stroke, of the use of thrombolytic therapy among patients with acute myocardial infarction (AMI), who do not fulfill accepted criteria or who have contraindications to thrombolytic therapy (i.e., overutilization) and among patients who are withheld thrombolytic treatment despite fulfilling i...

background: we sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely heberkinasa (heberbiotec, havana, cuba) and streptase (aventis behring gmbh, marburg, germany). methods: we conducted a double-blind randomized clinical trial to compare the two streptokinase formulations, i.e. heberkinasa (hbk) or streptase (stp), in patients...

background: streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. streptokinase is currently used in clinical medicine as a thrombolytic agent. it is naturally secreted by β-hemolytic streptococci. methods: to reach an efficient method of purification, an immunoaffinity chromatography method was developed that could puri...

Objective: The present study is aimed to investigate in vitro thrombolytic activity of three Bangladeshi medicinal plants Averrhoa bilimbi (Oxalidiaceae), Clerodendrum viscosum (Verbanaceae) and Drynaria quercifolia (Polypodiaceae). Materials and methods: Each the plant was extracted with methanol at room temperature and the concentrated methanolic extracts (MEF) were fractionated by the modifi...

BACKGROUND AND PURPOSE Ischemic stroke is an uncommon but devastating complication of myocardial infarction (MI). It is possible that delay in the acute revascularization of these patients influences the risk of peri-MI ischemic stroke independent of size of infarction or residual ventricular function. The influence of the timing and type of revascularization on risk of ischemic stroke in the p...

BACKGROUND The benefit of intravenous thrombolytic therapy in elderly patients with myocardial infarction is uncertain. There are no randomized trials of thrombolytic efficacy or observational studies of clinical effectiveness that focus specifically on the elderly. METHODS AND RESULTS To determine whether thrombolytic therapy for elderly patients is associated with a survival advantage in a ...

Limitations of CT Angiography in Patient Selection for Thrombolytic Therapy To the Editor: We have read with great interest the article by Wildermuth et al1 on the role of CT angiography (CTA) in patient selection for thrombolytic therapy. The authors report that selection of patients with little potential for benefit from thrombolytic therapy is feasible with the use of CTA. The CTA findings, ...

BACKGROUND AND PURPOSE The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review- At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were propos...